DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* TRANSGENE *


 

1979 - Alsace
Strasbourg
www.transgene.fr/us

 

Discovery, Immunology
Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases
Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products
Clients: Prescribers
communication@transgene.fr

Age: 38 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux]
Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome]
Med.Dir.-CMO: Adda (Nathalie) [M.D., ex-Vertex]
Fin.Dir.-CFO: Boissel (Stéphane) [MBA (Chicago), ex-PWC, Innate Pharma, Lazard]
BusDev:
Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public

Turnover (M€) : 5.6 (2009), 6.5 (2008), 3.2 (2006)
Total funding (M€) : 350
Last funding (M€) : 100.1
Focus : Vaccines
Position : Clinical
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2012 .09 Clinical trial (phase II) for JX594/TG6006 in Sorafenib-Refractory Liver Cancer Patients with Jennerex (interim, positive) CLIN [33 years]
2011 .05 Partnering development agreement with Innate Pharma for immunomonitoring services, with set-up of new company named Platine Pharma Services R&D [32 years]
2011 .03 Clinical trial (phase II) for TG4040 in chronic hepatitis C (recruitment completed, 154 patients) CLIN [32 years]
2011 .01 Partnering development agreement with Beckman Coulter for a companion diagnostic test for TG4010 R&D [32 years]
2010 .09 Partnering distribution agreement (also co-development) with Jennerex (USA) for Europe, CEI and Middle-East markets (exclusive distributor), concerning JX-594 (anticancer), along minorty share worth 3.8 M€ MKTG [31 years]
2010 .05 Public (and private) offering : 152 M€ millions d'euros (Institut Mérieux maintain 55.2 % of shares, as first stakeholder) PBO [31 years]
2010 .03 Licensing-out (exclusive option) of TG4010, for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications, to Novartis (10 MUS$ non-refundable option fee) LICOUT [31 years]
2009 .12 Designation of Fast Track Status by FDA for TG4010, a targeted immunotherapy for treatment of Non-Small Cell Lung Cancer MKTG [30 years]
2009 .05 Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon MKTG [30 years]
2007 .06 Public offering : 100.1 M€ PBO [28 years]
2007 .04 Licensing-out of HPV vaccine lead to Roche (terminated in February 2011) LICOUT [28 years]
2006 .07 Public offering : 14.3 M€, through exercise of warrants PBO [27 years]
2005 .06 Public offering : 34.9 M€, with refocus on therapeutic vaccines PBO [26 years]
2004 .12 Nomination : Philippe Archinard as CEO ORGN [25 years]
2002 .07 Nomination : Jean-François Carmier as CEO [ex-Transgene V.P.] ORGN [23 years]
2001 .09 Management restructuring : 30 heads employee reduction from 195 headcounts ORGR [22 years]
2001 .05 Public offering : 63.0 M€ in depositary shares for Biomérieux-Pierre Fabre and AFM (French Muscular Dystrophy Association), with refocus on cancer treatments PBO [22 years]
2000 .11 Nomination : Gilles Bélanger [ex-Biomérieux], as CEO ORGN [21 years]
1998 .03 Listing on Paris Nouveau Marché and New York Nasdaq : 100 MUS$ (about 80 M€) PBO [19 years]
1995 .00 Production : GMP manufacturing facility completed INDUS [15 years]
1992 .00 Nomination : Bernard Gilly as CEO, with refocus on gene transfer technology ORGN [12 years]
1979 .00 Company founded by Pierre Chambon (Ph.D., CNRS, Research Director at Pasteur Institute) and others ORGF [0 year]

Actualisation / Updating: 27-Dec-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende